Candel Therapeutics, Inc. (CADL) Financial Analysis & Valuation | Quarter Chart
Candel Therapeutics, Inc. (CADL)
CADLPrice: $5.58
Fair Value: 🔒
🔒score
Candel Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the development immunotherapies for the cancer patients. The company develops CAN-2409, which is in Phase II clinical trails for the treatment of pancreatic cancer; Phase III clinical trials for the treatment of prosta... more
Candel Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the development im... more
Description
Shares
| Market Cap | $306.35M | Exchange | NASDAQ |
| Sector | Healthcare | Industry | Biotechnology |
| Country | US | CEO | Paul-Peter Tak |
| IPO Date | 2021-07-27 | CAGR | — |
| Employees | 38 | Website | www.candeltx.com |
| Div. Yield | — | Payout Ratio | — |
| Buy Back Yield | — | Total Yield | — |
CADL chart loading...
Fundamentals
Technicals
| Enterprise Value | $249.87M | P/E Ratio | -9.96 |
| Forward P/E | -9.66 | PEG Ratio | — |
| P/S Ratio | 29400.89 | P/B Ratio | 365.97 |
| P/CF Ratio | -879.12 | P/FCF Ratio | -872.99 |
| EPS | $-0.56 | EPS Growth 1Y | -72.65% |
| EPS Growth 3Y | -1182.61% | EPS Growth 5Y | — |
| Revenue Growth 1Y | -43.69% | Gross Margin | -0.73% |
| Operating Margin | -40.66% | Profit Margin | -11.49% |
| ROE | -0.15% | ROA | -0.12% |
| ROCE | -0.49% | Current Ratio | 8.25 |
| Quick Ratio | 8.25 | Cash Ratio | 7.96 |
| Debt/Equity | 0.08 | Interest Coverage | -52.73 |
| Altman Z Score | 10.71 | Piotroski Score | 2 |